📊 NAUT Key Takeaways
Is Nautilus Biotechnology, Inc. (NAUT) a Good Investment?
Nautilus Biotechnology is a pre-revenue stage biotech company burning through cash at $52M annually with only $12.4M in cash reserves (~3 months runway). Despite a strong balance sheet with $157M equity and minimal debt, the company faces critical near-term funding risk absent material revenue generation or capital raises. The unsustainable cash burn trajectory and absence of revenue visibility present severe fundamental challenges.
Nautilus remains effectively pre-revenue with substantial net losses and deeply negative free cash flow, indicating unclear line-of-sight to self-sustaining operations. While the balance sheet shows high liquidity and no debt, cash burn is significant and raises financing risk absent near-term commercialization traction.
Why Buy Nautilus Biotechnology, Inc. Stock? NAUT Key Strengths
- Strong balance sheet with $157M stockholders' equity and zero long-term debt provides capital base for funding
- Excellent short-term liquidity with 13.33x current ratio demonstrates ability to meet near-term obligations
- Pre-revenue biotech model typical for laboratory instrumentation sector with potential long-term value creation if technology succeeds
- Very strong liquidity (13.33x current ratio)
- Zero leverage (0.00x D/E) provides flexibility
- Low capex intensity supports capital-light model
NAUT Stock Risks: Nautilus Biotechnology, Inc. Investment Risks
- Critical cash runway of approximately 3 months at current burn rate ($52M annual free cash flow burn vs $12.4M cash)
- Zero revenue generation with no visible near-term commercialization pathway or revenue drivers
- Annual net losses of $59M and operating losses of $1.8M indicate massive operating inefficiency and unproven business model
- Prolonged pre-revenue status and commercialization uncertainty
- High cash burn and negative FCF heighten financing/dilution risk
- Sustained negative ROE/ROA signal poor capital efficiency
Key Metrics to Watch
- Quarterly cash burn rate and total cash on hand (immediate existential metric)
- Revenue generation initiation and product commercialization milestones
- Secondary capital raises and equity offerings (necessary for survival at current burn rate)
- Total cash and marketable securities
- Operating cash flow (quarterly burn)
Nautilus Biotechnology, Inc. (NAUT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.33x current ratio provides a solid financial cushion.
NAUT Profit Margin, ROE & Profitability Analysis
NAUT vs Industrial Sector: How Nautilus Biotechnology, Inc. Compares
How Nautilus Biotechnology, Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nautilus Biotechnology, Inc. Stock Overvalued? NAUT Valuation Analysis 2026
Based on fundamental analysis, Nautilus Biotechnology, Inc. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nautilus Biotechnology, Inc. Balance Sheet: NAUT Debt, Cash & Liquidity
NAUT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nautilus Biotechnology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.56 indicates the company is currently unprofitable.
NAUT Revenue Growth, EPS Growth & YoY Performance
Nautilus Biotechnology, Inc. Dividends, Buybacks & Capital Allocation
NAUT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nautilus Biotechnology, Inc. (CIK: 0001808805)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772667437.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772663494.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772663489.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772663485.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772663480.xml | View → |
❓ Frequently Asked Questions about NAUT
What is the AI rating for NAUT?
Nautilus Biotechnology, Inc. (NAUT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NAUT's key strengths?
Claude: Strong balance sheet with $157M stockholders' equity and zero long-term debt provides capital base for funding. Excellent short-term liquidity with 13.33x current ratio demonstrates ability to meet near-term obligations. ChatGPT: Very strong liquidity (13.33x current ratio). Zero leverage (0.00x D/E) provides flexibility.
What are the risks of investing in NAUT?
Claude: Critical cash runway of approximately 3 months at current burn rate ($52M annual free cash flow burn vs $12.4M cash). Zero revenue generation with no visible near-term commercialization pathway or revenue drivers. ChatGPT: Prolonged pre-revenue status and commercialization uncertainty. High cash burn and negative FCF heighten financing/dilution risk.
What is NAUT's revenue and growth?
Nautilus Biotechnology, Inc. reported revenue of N/A.
Does NAUT pay dividends?
Nautilus Biotechnology, Inc. does not currently pay dividends.
Where can I find NAUT SEC filings?
Official SEC filings for Nautilus Biotechnology, Inc. (CIK: 0001808805) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NAUT's EPS?
Nautilus Biotechnology, Inc. has a diluted EPS of $-0.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NAUT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nautilus Biotechnology, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NAUT stock overvalued or undervalued?
Valuation metrics for NAUT: ROE of -37.6% (sector avg: 15%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy NAUT stock in 2026?
Our dual AI analysis gives Nautilus Biotechnology, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NAUT's free cash flow?
Nautilus Biotechnology, Inc.'s operating cash flow is $-50.7M, with capital expenditures of $1.3M.
How does NAUT compare to other Industrial stocks?
Vs Industrial sector averages: Net margin N/A (avg: 10%), ROE -37.6% (avg: 15%), current ratio 13.33 (avg: 1.8).